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Summary   
Bipolar-disorder, characterized by switches between depressive and manic mood, 
is treated by mood-stabilizers, lithium being one of them. Among hypotheses suggested, 
the inositol-depletion hypothesis proposes that lithium attenuates hyperactivation of 
phosphatidylinositol signaling linked to neurotransmission-related receptors. 
Available for us are knockout-mice of two genes (IMPA1 or Slc5a3) each 
encoding for a protein related to inositol metabolism. We previously characterized these 
mice as exhibiting lithium-like neurochemical and behavioral phenotype.  
We performed a DNA-microarray study searching for pathways commonly 
affected by chronic lithium treatment and by the knockout of each of the genes. Here we 
show up-regulation of mitochondrial function in the three paradigms studied. To verify 
this result, interrelationship between treatment with lithium and rotenone, an inhibitor of 
mitochondrial function, was studied behaviorally. Lithium and rotenone counteracted 
each other's effects in two bipolar-related models. The results support the inositol-
depletion hypothesis and suggest amelioration of aberrant mitochondrial function 
consequent to inositol-depletion.  
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Introduction 
Bipolar-disorder is a multifactorial and polygenic psychiatric-illness characterized 
by switches between depressive and manic mood. Lithium-salts (Li) are among the main 
drugs used in its treatment. The mechanism of Li's mood-stabilization is not yet 
unraveled. Among hypotheses of Li's mechanism the inositol-depletion hypothesis 
proposes that Li acts by depletion of brain myo-inositol1. This is based on the 
uncompetitive inhibition of inositol monophosphatase-1 (IMPase-1), a key enzyme in the 
phosphatidylinositol (PI) cycle, by therapeutically-relevant Li levels resulting in 
decreased myo-inositol (inositol) and subsequent down-regulation of the PI-cycle2. 
Berridge1 proposed that depletion of inositol leads to a decreased response to 
neurotransmission through this pathway. The inositol-depletion hypothesis is further 
supported by the observation that decrease in inositol is common to two other widely used 
mood stabilizers, valproic acid (VPA) and carbamazepine (CBZ)3,4. Williams et al.5 
demonstrated that the three mood-stabilizers inhibit the collapse of sensory neurons 
growth cones. This effect was reversed by addition of myo-inositol but not scyllo- or epi-
inositol6. 
  There are three sources of intracellular myo-inositol: 1. recycling in the PI cycle 
involving IMPase; 2. de-novo synthesis from glucose-6-phosphate via myo-inositol-1-
phosphate synthase (MIP-synthase); 3. uptake from extracellular fluid through a sodium-
myo-inositol cotransporter (SMIT) and the H+-myo-inositol cotransporter (HMIT). MIP-
synthase is inhibited by therapeutically-relevant VPA levels4. Chronic treatment with Li, 
VPA and CBZ decreased mRNA levels of SMIT1 in astrocytes7 corroborating with the 
finding that SMIT1 mRNA levels were up-regulated in neutrophils of bipolar patients8. 
Li-treatment affects three behavioral paradigms in rodents: Li-pretreatment induces 
hypersensitivity to pilocarpine-induced seizures9, chronic Li-treatment attenuates the 
amphetamine-induced hyperlocomotion model of mania10 and decreases immobility-time 
in the forced-swim test (FST) model of depression11,12.  
Homozygote-knockout (KO) of each of the IMPA1 or Slc5a3 genes encoding 
IMPase-1 and SMIT1, respectively, is lethal but both KO offspring are rescued by 
supplementation of 2% myo-inositol in drinking water to pregnant and lactating dams13,14. 
Adult KO IMPA1 mice exhibit ~50% reduction in brain IMPase activity with no 
difference in brain inositol levels14 and are characterized by Li-like behavior: reduced 
immobility in the FST and hypersensitivity to pilocarpine14. Adult Slc5a3 KO mice 
exhibit 60% reduction in brain inositol levels and also show Li-like reduced immobility in 
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the FST, hypersensitivity to pilocarpine-induced seizures14 and attenuated response to 
amphetamine-induced hyperlocomotion (unpublished data).  
Thus, there is behavioral and neurochemical similarity between Li-treated wildtype 
(WT) mice and mice harboring KO of either IMPA1 or Slc5a3, both encoding for proteins 
involved in inositol metabolism and known to be affected by chronic Li-treatment. It is 
plausible to expect that prolonged intervention with a biological system would induce 
changes in the expression of genes related to biofunctions involved in the resulting 
phenotype. We assumed that biofunctions similarly affected by chronic Li-treatment and 
by KO of IMPA1 or Slc5a3 would be those involved in the common phenotype relevant 
to the mood-stabilizing effects of Li.  Here we present a hypothesis-free micoarray study 
of frontal-cortex of untreated WT mice, Li-treated WT mice, IMPA1 KO mice (IMPA1 
KO) and Slc5a3 KO mice (SMIT1 KO) behaviorally verified by a pharmacological 
intervention. 
 
Results  
 
Gene expression analysis 
 
Since IMPA1 KO and SMIT1 KO mice were generated on different backgrounds 
the microarray analysis was carried out separately for each colony (further referred to as 
the SMIT1 colony or the IMPA1 colony). Three-way mixed model ANOVA of WT 
untreated and WT Li-treated mice from both colonies revealed that the major source of 
variation between the groups was the colony (Supplementary Fig. S2), supporting our a 
priory approach to perform the expression analysis separately for each colony.  
IMPA1 colony: in the frontal cortex of both IMPA1 KO mice and Li-treated WT 
mice as compared with WT-untreated mice 193 genes were similarly differentially 
expressed (either up- or down-regulated) at a level of p<0.05. SMIT1 colony: in the 
frontal cortex of both SMIT1 KO mice and Li-treated WT mice as compared with WT-
untreated mice 778 genes were similarly differentially expressed at a level of p<0.05. 
Hierarchical clustering of 4,643 genes differentially expressed by Li treatment or the KO 
in either of the colonies showed two major clusters of the samples corresponding to 
SMIT1 and IMPA1 colonies (Supplementary Fig. S3). Only one gene cluster consisting 
of 419 annotated genes showed similar expression pattern between the two colonies. 
Functional annotation of this gene cluster using DAVID software revealed that almost all 
functional annotations with FDR (false discovery rate)<0.05 are related to mitochondria, 
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specifically to respiratory function (Supplementary Fig. S4). Hierarchical clustering based 
on all differentially expressed genes in each colony separately (WT-Li vs. WT-untreated 
or KO vs. WT-untreated) revealed clustering of the KO samples with the Li-treatment 
samples (Fig. 1A,B). 
The expression of seven genes was significantly changed (p<0.05) in the same 
direction (up- or down regulation) in KO mice and Li-treated WT mice in both colonies 
(IMPA1 and SMIT1), as compared to their respective WT-untreated littermates 
(Supplementary Table S1). Four of the genes – Cox5a, Ndufab1, Ndufs7 and Uqcrfs1 - 
take part in the oxidative phosphorylation (OxPhos) pathway and were all up-regulated 
compared to WT-untreated mice. Three of these genes, Cox5a, Ndufs7 and Ndufab1 have 
previously been indicated by at least two independent studies to be down-regulated in 
bipolar patients or genetically associated with bipolar disorder15-18. 
 
Analysis using DAVID software 
For each colony genes with similar differential expression (p<0.05) in the frontal 
cortex of the KO mice and the Li-treated WT mice as compared to WT-untreated mice 
were uploaded onto the software. Out of the uploaded genes, 159 and 654 genes from the 
IMPA1 and SMIT1 colonies, respectively, were identified by the software and used for 
the analysis. In both colonies significantly enriched terms and significant KEGG 
pathways (Bonferoni corrected p<0.05, FDR<0.05) were composed of mitochondria-
related genes (Supplementary Fig. S5A,B). KEGG pathways significantly enriched in 
both colonies were Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and 
OxPhos. Since the pathophysiology of the three diseases involves mitochondrial 
dysfunction19, genes encoding for proteins of the electron transfer chain of OxPhos are 
included in their pathway. Hence, enrichment in OxPhos-related genes is identified by the 
software as enrichment in the pathways related to these three diseases. Indeed, almost all 
of the genes included in those pathways were part of the mitochondrial OxPhos chain. 
Within the OxPhos, the differentially expressed genes in both colonies belong to all 
complexes of the electron transfer chain except for complex II (Fig. 2A,B).     
 
Analysis using the GSEA software 
For both KOs the most significant gene-set found was 
“structural_constituent_of_ribosome” followed by various mitochondria-related gene-sets 
(Supplementary Table S2), all exhibiting up-regulation as compared to WT-untreated 
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mice. No significantly differentially expressed gene-sets were obtained in the Li-
treatment groups, a result possibly related to the phenomenon that Li affects diseased 
individuals much more than healthy controls and that the behavioral effects of the drug 
are observed in challenged animals and not under baseline conditions. 
 
Analysis using the IPA software 
As seen in Fig. S5A, using the cut-offs of p<0.05, f.c.>1.1 and p<0.035, f.c>1.15 
for the IMPA1 and SMIT1 colonies, respectively (as justified under the online available 
Methods), multiple biological functions were significantly affected both by Li treatment 
in the two colonies and by IMPA1 or Slc5a3 KO. The common significantly affected 
canonical pathways in the four groups (WT-Li treated mice from SMIT1 colony, WT-Li 
treated mice from IMPA1 colony, SMIT1 KO, IMPA1 KO) were OxPhos, mitochondrial 
dysfunction and ubiquinone biosynthesis, all related to mitochondria (Fig. S5B, Table 1). 
 
Rotenone-induced behavioral effects 
Based on our microarray results and previous reports of reduced mitochondrial 
function in bipolar patients15,20 we hypothesized that chronic mild inhibition of OxPhos 
would induce a bipolar disorder-like behavioral phenotype and that such behavior would 
be ameliorated by chronic lithium treatment. Chronic treatment with rotenone, an OxPhos 
complex I inhibitor, is used to model Parkinson’s disease.  However, the doses shown to 
elicit Parkinson’s-like effects are higher than those used in our study. No difference was 
found between rotenone-treated and untreated mice in weight, well being (monitored by 
the appearance of their fur and their home-cage behavior) or general motor function, 
confirming that rotenone concentration used did not affect the general condition of the 
animals. Mice exhibiting altered motor ability in either the hanging wire or the rotarod 
tests were excluded from further experiments.  
Four treatment groups of mice were studied behaviorally in the FST and the 
amphetamine-induced hyperlocomotion paradigm: regular food + vehicle (Rf+vehicle), 
chronic lithium treatment + vehicle (Li+vehicle), regular food + chronic rotenone 
treatment (Rf+rot), chronic lithium treatment + chronic rotenone treatment (Li+rot). In 
the FST, as expected11,12, lithium treatment exerted an antidepressant-like effect, reducing 
the immobility time as compared to both regular food groups, either rotenone-pretreated 
or vehicle-pretreated (Fig. 3). One-way ANOVA revealed a significant treatment effect 
(F=8.6173, df=3, p<0.00006). The effect of Li was stronger in vehicle-pretreated 
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(Rf+vehicle - 163 sec, Li+vehicle - 94 sec, Fisher's LSD post-hoc test, p<0.0001) than in 
rotenone-pretreated animals (Rf+rot – 170 sec, Li+rot – 132 sec, p<0.03). Chronic 
treatment with rotenone (Rf+rot) did not have a significant effect on the immobility time, 
though a consistent trend of increased immobility was observed in all four experiments. 
However, rotenone treatment significantly prevented the effect of lithium (p<0.005) (Fig. 
3).  
In the amphetamine-induced hyperlocomotion paradigm there was no difference 
among the groups prior to amphetamine administration. Rotenone augmented 
amphetamine-induced hyperlocomotion and Li treatment abolished this effect (Fig. 4). 
Two-way repeated measures ANOVA of the results following amphetamine 
administration indicated a significant treatment effect (F=7.33, df=3, p<0.0005) and 
timeXtreatment interaction (F=2.77, df=15, p<0.0006). Post-hoc analysis indicated that 
rotenone’s augmentation of the effect of amphetamine was statistically significant 
(Fisher's LSD post-hoc test, p<0.025) and so was Li’s effect to abolish rotenone's effect 
on amphetamine-induced hyperlocomotion (Fisher's LSD post-hoc test, p<0.0002) (Fig. 
4). 
 
Discussion 
The first part of the present study was a hypothesis-free DNA microarray analysis 
looking for pathways underlying the mood-stabilizing effect of Li in mouse frontal 
cortex. We searched for shared gene expression patterns among Li-treated mice and mice 
harboring KO of either IMPA1 or Slc5a3, both encoding proteins related to the PI cycle 
and shown to be affected by therapeutic levels of the drug. Our group has previously 
reported Li-like behavioral and neurochemical phenotypes exhibited by IMPA1 KO or 
SMIT1 KO mice14. The three different bioinformatics approaches used to analyze the 
microarray data consistently indicated involvement of mitochondrial function in the Li-
like phenotype. This finding corroborates previous reports of down-regulation of 
mitochondria-related genes16,17, mitochondrial dysfunction20 and mitochondrial structural 
abnormalities21 in bipolar patients. The results are also consistent with studies showing 
beneficial effects of mood stabilizers on mitochondrial function22,23 and oxidative stress24. 
The striking similarity in biological functions and canonical pathways affected by Li-
treatment and each of the KOs provides support for the inositol-depletion hypothesis and 
suggests that inositol metabolism is involved in Li's effect on OxPhos and mitochondrial 
function.     
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DNA microarray studies frequently seek confirmation using real-time PCR 
technique to verify the expression of specific genes found to be differentially expressed in 
the microarrays following a particular intervention. However,  as discussed by Konradi et 
al.25 in a recent review, the strength of transcriptome studies, such as microarrays, is the 
examination of the expression pattern of inter-related groups of genes.  The likelihood for 
a concordant expression change in a group of genes with a similar function or location is 
much smaller than the likelihood to reach a significant change for an individual gene. 
Moreover, systemic analysis of gene expression obscures individual biological 
differences and smooths experimental bias, highlighting the main between-group 
differences. For example, the well established upregulation of BDNF and BCL-2 by 
chronic lithium treatment26  is not robustly reflected in microarray studies27. There are at 
least two possible explanations for this phenomenon: 1. The use of stringent statistical 
tests such as correction for multiple testing and of relatively high cut-off values for the 
analysis of microarray data indeed decrease the number of “false-positive” differentially 
expressed genes, but at the cost of increased number of “false negatives”, excluding genes 
with small but true fold of change and relatively high variance. 2. An organism is a 
complex network with multiple points of regulation. The activity of an enzyme or the 
level of a metabolite may be affected at the level of genetics, epigenetics, change in the 
levels of transcription factors, alternative splicing, existence of iRNAs, translation or 
degradation rate, activity of isoenzymes, etc. It is reasonable to assume that each 
individual has his own “network setup” which defines his personal response to 
environmental factors intervening with the network. Thus, particularly in multifactorial 
disorders, the expression level of a single gene would be a poor indicator of upstream 
causative factors or of the downstream consequences responsible for a final outcome. 
Indeed, several microarray studies were carried out to unravel the pathophysiology of 
bipolar disorder using different species, tissues, and mood-stabilizer treatment 
regimes16,17,27, yet, among the reported candidate genes almost none replicated between 
the studies. On the other hand, quite a few of the studies indicated down-regulation of 
mitochondria-related genes in bipolar patients, with components of the electron transport 
chain in particular16,17 and up-regulation of these biological components following 
chronic Li treatment23. 
Rather than confirming the microarray results by measuring mRNA levels of 
particular genes found to be differentially expressed, the second part of the study aimed to 
model the mitochondrial aspect of the pathophysiology of bipolar disorder and assess the 
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interaction between the effect of mild chronic treatment with rotenone and Li on bipolar-
related behavioral paradigms in mice. As hypothesized, rotenone, a mitochondrial 
OxPhos complex I inhibitor, and Li exhibited counteracting effects in the FST model of 
depression and in the amphetamine-induced hyperlocomotion model of mania, supporting 
an interrelationship between Li’s mood-stabilizing effect and mitochondrial function. 
In the FST, rotenone treatment did not significantly affect the performance of the 
mice, possibly due to a ceiling effect, but it did significantly increase the immobility time 
of Li-treated mice. Namely, the antidepressant-like effect of Li on rotenone-treated mice 
was significantly lower than that on vehicle-treated mice. This is reminiscent of the 
situation in the clinics, where Li is regarded to be a better anti-manic and prophylactic 
agent than an antidepressant. It is possible that the pathophysiology accumulated prior to 
the commencement of Li treatment as modeled here by rotenone pretreatment can not be 
fully reversed by Li.  
In the amphetamine-induced hyperlocomotion paradigm rotenone significantly 
augmented the effect of amphetamine, reminiscent of the increased sensitivity to 
psychostimulants of euthymic bipolar patients. Li treatment completely abolished 
amphetamine's effect both in vehicle-pretreated and rotenone-pretreated mice. Prior to 
amphetamine challenge no behavioral differences were observed among the groups, 
resembling euthymic patients or subjects with predisposition to bipolar disorder but yet 
asymptomatic.  
Results obtained from behavioral paradigms should be interpreted cautiously since 
rodents commonly used in these studies are healthy. They do not possess the genetic or 
physiological deviations characterizing bipolar patients. Bipolar disorder-related 
behavioral animal models are based on a limited number of often poorly understood 
behavioral phenotypes and speculated susceptibility genes. The models are frequently 
strictly environmental, acute or subchronic (such as the FST, tail suspension test, 
psychostimulant-induced behaviors, dominant and submissive relationship) or based on 
specific gene knockouts, potentially involving undefined compensatory mechanisms. 
Thus, the observed effects of a drug (e.g. Li) in these models would most probably be 
more modest than (in the case of an acute model) or even unrelated to (as in the case of 
gene knockout models) those seen in patients. This might have caused the relatively small 
changes obtained in the microarray paradigm of the present study and is further supported 
by our behavioral results. As recently suggested by the members of a targeted expert 
meeting of the European College of Neuropsychopharmacology  (ECNP)28 an improved 
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model to investigate a multifactorial disorder would be one that resembles the progress of 
the illness in patients, e.g. mild but prolonged induction of pathophysiology assumed to 
be involved in the disorder. Such a model is expected to exhibit a disorder phenotype only 
following prolonged intervention and when additional risk-factors occur. We aimed to 
create such a model using chronic low doses of rotenone, modeling the reported 
mitochondrial dysfunction in bipolar patients15,16,20. This fits the concept that the disorder 
involves gradual decrease in mitochondrial function, with symptoms beginning only 
when a threshold is reached or when an event occurs which requires fully functional cells, 
making the subject more vulnerable to environmental factors targeting mitochondrial 
function. Amphetamine, a psychostimulant widely used to model mania was shown to 
inhibit respiratory chain activity, an effect reversed by Li or VPA treatment23. Although 
single-photon emission computed tomography (SPECT) imaging did not find increased 
striatal dopamine in euthymic bipolar patients in response to amphetamine as compared to 
healthy subjects the patients exhibited greater behavioral response to the 
psychosymulant29, suggesting an increased sensitivity to the drug even during the 
euthymic stage. Interestingly, some but not all studies report that antidepressants induce 
an inhibitory effect on mitochondrial complexes and a decrease in mitochondrial 
membrane potential (∆Ψm)30. It is tempting to speculate that these effects underly 
antidepressant-induced mania in bipolar patients.   
Mitochondria are the main source of cellular energy obtained as adenosine 
triphosphate (ATP) through the OxPhos pathway. However, energy homeostasis is only 
one of several essential processes related to mitochondrial function. Other well 
recognized processes are apoptosis31 and calcium buffering and homeostasis32,33. IP3, one 
of the two PI cycle-related second messengers, binds to its receptor (IP3R) located on the 
endoplastic reticulum (ER) membrane, resulting in Ca2+ secretion. Previous studies 
demonstrated proximity of IP3R to mitochondria and rapid increase in mitochondrial Ca2+ 
levels following IP3-induced Ca2+ release32. Rapid elevation of mitochondrial Ca2+ 
induces opening of the mitochondrial permeability transition pore (MPT) in the inner 
membrane34, which might result in decreased mitochondrial membrane potential, 
decreased mitochondrial function and increased production of reactive oxygen species 
(ROS)34,35. Kubota et al.36 demonstrated that inhibition of cyclophilin D (CypD), a protein 
known to be part of the MPT, improved the abnormal behavior of mitochondrial DNA 
polymerase (Polg1) KO mice, suggested by the authors as an animal model of bipolar 
disorder36. Expression of PPIF, the gene encoding for the CypD protein, was found to be 
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down-regulated both in the brains of bipolar patients and in the Polg1 mutant mice, 
possibly due to a compensatory mechanism36.  
Over the last decade, evidence accumulated regarding a reciprocal relationship 
between mitochondria and autophagy37, a cellular pathway required for proper lysosomal 
degradation of misfolded proteins and their aggregates, long-lived proteins, damaged 
organelles and pathogens. Several studies reported that the three mood-stabilizers Li, 
VPA and CBZ, all known to reduce inositol levels5 upregulate autophagy38,39. Increased 
autophagy was also achieved by treatment with the specific IMPase inhibitor L-690,330 
but not the GSK-3β inhibitor SB21676338. Furthermore, the pro-autophagic effect of Li 
was reversed by addition of myo-inositol38, indicating the involvement of inositol-
depletion in the effect of the three mood stabilizers on autophagy. Interestingly, 
Parkinson's disease, Alzheimer’s disease, Huntington's disease and Amyotrophic Lateral 
Sclerosis (ALS), all neurodegenerative diseases which exhibit well established 
involvement of mitochondrial dysfunction19, are also related to aberrant autophagy40, and 
were suggested to benefit from Li treatment41. Recent studies reported that cells lacking 
mitochondrial DNA (mtDNA) or functional OxPhos complexes display impaired 
autophagy42 and that autophagy is required for the maintenance of mtDNA under nitrogen 
starvation in yeast43. Thus, it is possible that mitochondrial function and autophagy are 
interconnected, with alterations in one of the processes initiating a vicious cycle of 
accumulating dysfunctions. Our present findings that inositol-depletion possibly underlies 
Li’s effect on mitochondrial function raise the question whether inositol-depletion 
directly affects only one of the two processes, which, in turn, projects on the function of 
the other, or whether an independent effect is exerted on the two interconnected 
pathways. Intriguingly, rapamycin, an autophagy activator, was reported to protect 
against rotenone-induced apoptosis via induction of autophagy44. A similar effect of 
protection against rotenone-induced apoptosis was obtained by Li or VPA treatment24, an 
effect interpreted by the authors as related to the beneficial effect of the two mood-
stabilizers on oxidative stress and OxPhos.    
In summary, this is the first report of a whole genome gene expression study 
carried concomitantly in Li-treated mice and in mice exhibiting Li-like behavior induced 
by KO of one of two genes, both encoding proteins belonging to a particular pathway and 
known to be affected by Li. We replicated results of previous studies both at the level of 
single genes and at the level of systems biology, giving credence to our experimental 
design. Based on our microarray findings and using a pharmacological intervention we 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
31
8.
1 
: P
os
te
d 
31
 A
ug
 2
01
1
induced bipolar-like behavior, reversed by Li treatment. Our results support the inositol-
depletion hypothesis of Li's mechanism of action and suggest that mitochondrial 
dysfunction might be involved in the pathophysiology of bipolar disorder ameliorated by 
mood stabilizers via their effect on inositol metabolism. 
 
Methods Summary 
Fig. S1 (supplementary information) presents a schematic layout of the study. 
Microarrays 
Each of the SMIT1 and IMPA1 KO mice were maintained in a separate colony by 
breeding heterozygote males and females. Chronic lithium treatment was carried out as 
previously described12. Serum Li levels were 0.9 mmol/L ± 0.4 (SD). In each of the 
SMIT1 and IMPA1 colonies three groups (4 mice/group) were examined: WT-untreated, 
WT-Li treated and KO (IMPA1 or SMIT1). Extracted RNA was hybridized to Affimetrix 
Mouse Gene 1.0 ST chips. Initial data analysis was carried out using the Partek® and 
SpotFire software. Three-way mixed-model ANOVA was used to analyze the difference 
between the colonies regarding Li's effect. Subsequently, two-way mixed-model ANOVA 
was carried out separately in each colony to assess the effect of Li-treatment and of the 
KO of each of the genes. Differentially-expressed genes were defined as those having 
p<0.05 compared to WT-untreated mice. For clustering analysis, signals were batch-
corrected using Partek®. Genes showing differential expression in either Li-treated 
animals or KO animals were included in the analysis. The Hierarchical Clustering tool of 
the SpotFire software was used to create dendrogram of z-score-transformed signals. 
Bioinformatics analysis was carried out using the DAVID, GSEA and IPA software. 
Behavior 
ICR mice were injected subcutaneously once daily with rotenone (0.5 mg/kg) or 
vehicle for 4 weeks. Chronic Li regime was applied during the last two weeks of 
injections. After four weeks all animals were evaluated for motor function by the hanging 
wire and the rotarod tests a day prior to the behavioral paradigms. The FST and 
amphetamine-induced hyperlocomotion were performed on consecutive days. Effect of 
treatment on behavior in the FST was analyzed using ANOVA followed by Fisher’s LSD 
post-hoc test. Repeated-measures ANOVA followed by Fisher’s LSD post-hoc test was 
used to assess the effect on amphetamine-induced hyperlocomotion. 
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Table 1. Canonical pathways found by the IPA software to be significantly affected in the frontal 
cortex of Li-treated WT mice and IMPA1 or SMIT1 KO mice 
 
 
Gene expression data of the SMIT1 KO mice, Li-treated WT mice from the SMIT1 colony (SMIT_Li), 
IMPA1 KO mice and Li-treated WT mice from the IMPA1 colony (IMPA_Li) was subjected to IPA 
canonical pathway analysis. Genes from the uploaded data sets that met the cut-offs (p<0.05, f.c.>1.1 
and p<0.035, f.c.>1.15 for the IMPA1 and the SMIT1 colonies, respectively) and that were associated 
with a canonical pathway in the Ingenuity Knowledge Base were considered for the analysis.  
* Ratio indicates the number of genes from the data set that map to the pathway divided by the total 
number of genes that map to the canonical pathway. Fisher’s exact test was used to calculate the p‐value 
determining the probability that the association between the genes in the dataset and the canonical 
pathway is explained by chance only.  
Canonical Pathway 
p-value 
IMPA1 KO 
Ratio*      
IMPA1 KO 
p-value 
IMPA_Li 
Ratio      
IMPA1_Li 
p-value  
SMIT1 KO
Ratio      
SMIT1 KO 
p-value 
SMIT_Li 
Ratio       
SMIT_Li 
OxPhos 6.77E-06 17/166 2.43E-04 13/166 5.14E-03 10/166 3.86E-06 19/166 
Mitochondrial 
dysfunction 
8.17E-05 14/125 2.25E-02 8/125 1.26E-04 12/125 3.89E-06 17/125 
Ubiquinone 
biosynthesis 
2.33E-04 10/119 1.48E-03 8/119 1.41E-02 7/119 2.12E-03 9/119 
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Figure legends 
 
Hierarchal clustering of differentially-expressed genes show clustering of Li-treated 
mice with both SMIT1 KO (A) and IMPA1 KO (B) mice 
Two-way ANOVA was carried out separately in each colony to reveal genes whose 
expression was affected by Li treatment or KO of either IMPA1 or Slc5a3 as compared to 
WT-untreated mice. Heatmaps and dendrograms were created separately for each colony. 
Genes differentially expressed (p<0.05) in either KO mice or in Li-treated mice (2,813 
and 2,136 genes in SMIT1 (A) and IMPA1 (B) colony, respectively) were used for the 
analysis. Z-score calculation and cluster analysis were carried out for each colony 
separately. Colored bars represent the type of mice (yellow – WT-untreated, pink – KO, 
grey – WT-Li treated). Each raw represents an individual gene and each column a mouse. 
Green=negative Z-score; Red=positive Z-score.  
 
Fig. 2: Localization of the commonly differentially expressed genes among the 
different complexes of the respiratory chain 
The OxPhos pathway is depicted. Asterisks denote genes with similar differential 
expression in KO mice and Li-treated WT mice compared to WT-untreated mice in the 
SMIT1 colony (A) and the IMPA1 colony (B). In both colonies the commonly 
differentially expressed genes were located in all the respiratory complexes except for 
complex II.  
 
 
Fig. 3: Prevention of Li’s antidepressant-like effect in the FST by chronic rotenone 
treatment 
Animals were placed for 6 minutes in a glass cylinder filled with water at a temperature 
of 240C such that the mouse could not touch the bottom or climb out of the cylinder. The 
duration of immobility was monitored during the last four min of the six min test.  
Results are means +/- S.E.M.  
Rf – regular food; Li – lithium-supplemented regular food; vehicle – 0.5% DMSO in 
saline; rot – rotenone. ANOVA revealed a significant treatment effect (F=8.6173, df=3, 
p<0.00006). Rotenone did not affect the immobility time; lithium significantly reduced 
the immobility time. Rotenone prevented the effect of lithium. Fisher's LSD post-hoc test: 
* p<0.05 compared to Li+vehicle, # p<0.05 compared to Li+rot. 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
31
8.
1 
: P
os
te
d 
31
 A
ug
 2
01
1
 Fig. 4: Prevention of rotenone-augmented amphetamine-induced hyperlocomotion 
by Li-treatment  
Mice were placed individually into monitor boxes and their behavior was digitally 
recorder for 30 min (habituation period). After 30 min mice were injected 1.5 mg/kg d-
amphetamine i.p. and digitally recorded for one hour. Distance moved was analyzed 
using the Ethovision system.  
Results are means +/- s.e.m.  
No difference was found among the groups prior to amphetamine injection. Repeated 
measures ANOVA of the results following amphetamine treatment revealed a significant 
treatment effect (F=7.33, df=3, p<0.0005) and timeXtreatment interaction (F=2.77, 
df=15, p<0.0006). Rotenone significantly augmented the effect of amphetamine (Fisher's 
LSD post-hoc test, p<0.025). Li treatment prevented the effect of rotenone on 
amphetamine-induced hyperactivity (Fisher's LSD post-hoc test p<0.0002). 
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Fig. 1: Hierarchal clustering of differentially-expressed genes show clustering of Li-treated mice 
with both SMIT1 KO (A) and IMPA1 KO mice (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Localization of the commonly differentially expressed genes among the different complexes of 
the respiratory chain. 
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Fig. 3: Prevention of Li’s antidepressant-like effect in the FST by chronic rotenone 
treatment 
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Methods 
 
Animals 
Male, eight weeks old mice were used in all the experiments. Animals were maintained 
on a 12h/12h light/dark cycle (lights on between 8:00 a.m and 8:00 p.m.) with ad libitum 
access to food and water. All tests were performed during the light phase of the cycle 
between 9:00 am and 7:00 pm. SMIT1 and IMPA1 KO mice were originally generated as 
previously described13,45. Each KO is maintained in a separate colony in our animal-care 
facility by breeding heterozygote males and females. Myo-inositol supplementation in 
drinking water to pregnant and lactating dams is used to rescue the KO mice. Genotyping 
was carried out as previously described45,46. ICR mice (Harlan, Israel) were allowed to 
acclimatize to the new environment for one week before treatment initiation. All 
experiments were approved by the Ben-Gurion University animal experimentation ethics 
committee. 
Chronic lithium treatment 
Chronic lithium treatment was carried out as previously described12. Animals 
were weighed every two days during the treatment period. The measured serum Li levels 
following this treatment regime were 0.89 mmol/L ± 0.43 (s.d.). 
RNA extraction 
Total RNA was extracted from frontal cortex specimens using TRI reagent 
(Sigma-Aldrich, St. Louis, MO) followed by purification using the RNeasy kit (Qiagen, 
Germantown, MD). RNA concentration was determined spectrophotometrically 
(GeneQuant, Pharmacia).  
DNA Microarray gene expression 
Since IMPA1 KO and SMIT1 KO mice were generated on different backgrounds 
(C57BL/129X1/Svj for SMIT1 and C57BL6/129Sv/EvBrd for IMPA1), the microarray 
analysis was carried out separately for each colony. In each colony three groups with four 
animals per group were examined: WT-untreated, WT-Li treated and KO (IMPA1 or 
SMIT1). Extracted RNA was hybridized to Affimetrix Mouse Gene 1.0 ST chips. 
Hybridization was carried out at the DNA microarrays and DNA sequencing Laboratory 
of the National Institute for Biotechnology in the Negev, Beer-Sheva, Israel, affiliated to 
our university. 
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Statistical analysis of the DNA microarrays  
Initial data analysis was supervised by V.C-C. from the Bioinformatics Core Facility, 
National Institute for Biotechnology in the Negev, using the Partek® and SpotFire 
software. Briefly, signals were log2 transformed and preprocessed using the robust multi-
chip average (RMA) method47.  Principal component analysis (PCA) was performed for 
each colony separately. In both cases, a batch effect was found, which was balanced with 
regard to the biological groups. Probe sets with log2-transformed signals below a value of 
five in all samples were considered as “noise” and excluded from further analysis. 
Initially, three-way mixed model ANOVA was used to analyze the difference between the 
colonies regarding the effect of Li. The following effects were included in the analysis: 
WT-Li vs. WT-untreated as the biological effect, colony (IMPA1 or SMIT1) and batch as 
random effects (batch effect included in the colony). Subsequently, two-way mixed 
model ANOVA was carried out separately in each colony to assess the effect of Li 
treatment and of the KO of each of the genes. The following effects were used in the 
analysis: type (WT-untreated, WT-Li treated, KO) as the biological effect and batch as 
the random effect. Differentially expressed genes were defined as those having p<0.05 
compared to WT-untreated mice. 
For clustering analysis, signals were batch-corrected using Partek® software. 
Genes showing differential expression in either Li-treated animals or KO animals were 
included in the analysis. The Hierarchical Clustering tool of SpotFire software was used 
to create heatmap and dendrogram of z-score transformed signals.  
Network and pathway analysis  
The Functional Annotation Tool in DAVID 6.7 (the Database for Annotation, 
Visualization and Integrated Discovery) bioinformatics software was used according to 
the publisher's recommendations48 for enrichment analysis of the genes differentially 
expressed in the same direction in the KO mice and Li-treated WT mice compared to 
WT-untreated mice in each colony.  
The raw data of the microarray results was uploaded onto the Gene Set 
Enrichment Analysis (GSEA) V2.5 software49, a computational method that determines 
whether an a priori defined set of genes (“gene-sets”) shows statistically significant 
concordant differences between two biological states. GSEA calculates an enrichment 
score (ES) for a given gene-set using a ranked list of genes. The rank represents the 
correlation between the expression of the gene and the phenotype. ES is calculated by 
walking down the ranked list of genes, increasing a running-sum statistic when a gene is 
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in the gene-set and decreasing it when it is not. Further, the software infers the statistical 
significance of each ES against background ES distribution calculated by randomly 
shuffling the labels on the samples (phenotype permutation) or by creating random gene-
sets matching the actual size of a particular gene-set (gene_set permutation). Given the 
relatively small sample size in our study we used the setup of 1000 gene-set permutations 
for analysis and a false discovery rate (FDR) cut-off of q-value<0.05 in order to identify 
differentially expressed sets of genes, as advised by the software team 
(http://www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html), using an a priory 
defined sets of genes (GO gene-set collection “c5.all.v2.5.symbols”).  
 Data was further analyzed through the use of IPA (Ingenuity® Systems, 
www.ingenuity.com) to identify pathways and functions affected by IMPA1 KO, Slc5a3 
KO and Li treatment. In order to reach the recommended number of genes to be used in 
the analysis the cut-offs for p-value and fold of change (f.c.) were set to p<0.05, |f.c.|>1.1 
and p<0.035, |f.c|>1.15 for the IMPA1 and the SMIT1 colonies, respectively. The 
functional analysis identifies the biological functions and/or diseases that were most 
significant to the data set. Genes from the uploaded dataset that met the cut-offs 
mentioned above and were associated with biological functions and/or diseases in the 
Ingenuity Knowledge Base were considered for the analysis. Right‐tailed Fisher’s exact 
test was used to calculate a p‐value determining the probability that each biological 
function and/or disease assigned to that data set is due to chance only. 
Canonical pathway analysis was used to identify the pathways in the IPA library 
of canonical pathways that were most significant to the uploaded data set. Genes from the 
data set that met the above mentioned cut-offs and were associated with a canonical 
pathway in the Ingenuity Knowledge Base were considered for the analysis. The 
significance of the association between the data set and the canonical pathway was 
measured in two ways: 1) A ratio of the number of genes from the data set that map to the 
pathway, divided by the total number of molecules that map to the canonical pathway. 2) 
Fisher’s exact test was used to calculate a p‐value determining the probability that the 
association between the genes in the dataset and the canonical pathway is explained by 
chance only.  
Drugs 
Rotenone (Sigma-Aldrich, St. Louis, MO) was dissolved in 0.5% DMSO in saline 
and injected subcutaneously (s.c.), 0.5 mg/kg and 5 ml/kg. d-Amphetamine (Sigma-
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Aldrich, Gillinfhuam, UK) was dissolved in saline and injected intraperitonealy (i.p), 1.5 
mg/kg and 10 ml/kg. 
Rotenone treatment 
ICR mice were injected once daily s.c. with rotenone or vehicle for 4 weeks. After 
two weeks of injections each of the groups was divided into two subgroups of Li 
treatment and regular food as described above for lithium treatment. All animals were 
daily weighed and their general well being was assessed by examination of their fur, 
general appearance and home-cage behavior.  After four weeks of treatment all animals 
were evaluated for motor function by the hanging wire and rotarod tests a day prior to the 
behavioral paradigms. Animals with aberrant performance in either of the tests were 
excluded from further experiments. The FST and amphetamine-induced hyperlocomotion 
were performed on consecutive days. Four experiments were carried out, each including 
four treatment groups with 5 mice/group.   
Hanging wire test 
Each animal was placed on a metal grid which was gently shacked to cause 
grabbing reflex and slowly turned upside down. Latency to fall was counted during a 
session of one minute.   
Rotarod test 
Animals were subjected to a series of one minute sessions separated by 10 
minutes on the rotarod apparatus (ROTA-ROD/RS, Letica Scientific Instruments, Panlab, 
Barcelona, Spain) using the following protocol: 0 rpm, 4 rpm, three sessions of 
accelerating 4 rpm to 40 rpm (two training sessions followed by the test session). Latency 
to fall was counted for each session.  
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Supplementary Information 
 
Supplementary Table S1:  Genes with common expression change in IMPA1 KO, SMIT1 KO 
and Li treated mice  
 
Gene 
symbol Entrez Gene Name 
p-value 
SMIT 
KO 
Fold of 
change 
SMIT 
KO 
p-value 
SMIT_
Li 
Fold of 
change 
SMIT_
Li 
p-value 
IMPA 
KO 
Fold of 
change 
IMPA 
KO 
p-value 
IMPA_
Li 
Fold of 
change 
IMPA_
Li 
Cox5a * Cytochrome c oxidase, subunit Va 0.004 1.27 0.007 1.22 0.02 1.16 0.016 1.18 
Gaa glucosidase, alpha, acid 0.03 -1.32 0.01 -1.4 0.015 -1.2 0.036 -1.16 
Gemin4 gem (nuclear organelle) associated protein 4 0.016 -1.18 0.003 -1.25 0.013 -1.12 0.006 -1.15 
Ndufab1* 
NADH dehydrogenase 
(ubiquinone) 1, alpha/beta 
subcomplex, 
0.019 1.16 0.005 1.2 0.01 1.2 0.03 1.14 
Ndufs7* NADH dehydrogenase (ubiquinone) Fe-S protein 7 0.042 1.2 0.02 1.22 0.014 1.15 0.02 1.13 
Rc3h1 RING CCCH (C3H) domains 1 0.02 -1.11 0.0005 -1.22 0.04 -1.08 0.02 -1.1 
Uqcrfs1 
ubiquinol-cytochrome c 
reductase, Rieske iron-
sulfur polypeptide 1 
0.03 1.15 0.0008 1.3 0.009 1.2 0.04 1.14 
 
Seven genes were found to be similarly differentially expressed in SMIT1 KO mice, Li-treated WT mice from the SMIT1 
colony (SMIT_Li), IMPA1 KO mice and Li-treated WT mice from the IMPA1 colony (IMPA_Li) as compare to their WT-
untreated littermates. Four of these genes participate in the oxidative phosphorylation pathway, all up-regulated compared to 
WT untreated mice. Asterisk indicates genes previously reported to be down-regulated in or genetically associated with bipolar 
disorder in at least two independent studies. 
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Supplementary Table S2: Gene_sets showing significant difference between KO mice and 
WT-untreated mice  
IMPA1 KO mice vs. WT-untreated mice 
     NES*** p-value FDR q-value** Size* NAME 
2.15 < 1.00E-04 2.14E-03 77 STRUCTURAL CONSTITUENT OF RIBOSOME 
2.01 < 1.00E-04 1.02E-02 50 MITOCHONDRIAL MEMBRANE PART 
1.99 < 1.00E-04 8.56E-03 300 MITOCHONDRION 
1.90 < 1.00E-04 3.86E-02 132 MITOCHONDRIAL PART 
-2.30 < 1.00E-04 8.90E-04 18 SYNAPSE ORGANIZATION AND BIOGENESIS 
-2.19 < 1.00E-04 4.45E-03 15 SYNAPTOGENESIS 
-2.08 < 1.00E-04 1.02E-02 22 EXTRACELLULAR STRUCTURE ORGANIZATION AND BIOGENESIS 
SMIT1 KO mice vs. WT-untreated mice 
NES p-value FDR q-value Size NAME 
2.69 < 1.00E-04 < 1.00E-04 77 STRUCTURAL CONSTITUENT OF RIBOSOME 
2.35 < 1.00E-04 < 1.00E-04 121 RIBONUCLEOPROTEIN COMPLEX 
2.34 < 1.00E-04 < 1.00E-04 35 RIBOSOME 
2.23 < 1.00E-04 1.93E-04 21 ORGANELLAR RIBOSOME 
2.20 < 1.00E-04 3.18E-04 21 MITOCHONDRIAL RIBOSOME 
2.12 < 1.00E-04 2.11E-03 42 MITOCHONDRIAL MATRIX 
2.10 < 1.00E-04 2.16E-03 42 MITOCHONDRIAL LUMEN 
2.09 < 1.00E-04 2.10E-03 19 RIBOSOMAL SUBUNIT 
2.02 < 1.00E-04 5.68E-03 130 MITOCHONDRIAL PART 
2.00 < 1.00E-04 6.55E-03 50 MITOCHONDRIAL MEMBRANE PART 
-2.30 < 1.00E-04 2.32E-03 78 ACTIVE TRANSMEMBRANE TRANSPORTER ACTIVITY 
-2.24 < 1.00E-04 1.72E-03 42 TRANSMEMBRANE RECEPTOR PROTEIN KINASE ACTIVITY 
-2.19 < 1.00E-04 1.92E-03 321 RECEPTOR ACTIVITY 
-2.17 < 1.00E-04 1.44E-03 46 PROTEIN TYROSINE KINASE ACTIVITY 
-2.14 < 1.00E-04 2.32E-03 29 METALLOPEPTIDASE ACTIVITY 
-2.14 < 1.00E-04 1.94E-03 34 TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE ACTIVITY 
-2.10 < 1.00E-04 3.17E-03 27 SECONDARY ACTIVE TRANSMEMBRANE TRANSPORTER ACTIVITY 
-2.10 < 1.00E-04 3.20E-03 246 SUBSTRATE SPECIFIC TRANSPORTER ACTIVITY 
-2.07 < 1.00E-04 4.42E-03 232 TRANSMEMBRANE TRANSPORTER ACTIVITY 
-2.05 < 1.00E-04 5.50E-03 225 TRANSMEMBRANE RECEPTOR ACTIVITY 
-2.04 < 1.00E-04 5.21E-03 216 SUBSTRATE SPECIFIC TRANSMEMBRANE TRANSPORTER ACTIVITY 
-2.01 < 1.00E-04 7.01E-03 167 ION TRANSMEMBRANE TRANSPORTER ACTIVITY 
-2.00 3.63E-03 7.54E-03 16 SYMPORTER ACTIVITY 
-2.00 < 1.00E-04 7.43E-03 138 CATION TRANSMEMBRANE TRANSPORTER ACTIVITY 
-1.96 1.94E-03 1.24E-02 20 CELL PROJECTION BIOGENESIS 
-1.92 < 1.00E-04 1.90E-02 26 ANION TRANSMEMBRANE TRANSPORTER ACTIVITY 
-1.89 < 1.00E-04 2.51E-02 224 MEMBRANE FRACTION 
 
* Size – number of genes included in a particular gene-set.  
** FDR q-value – false discovery rate, adjusted to the gene-set size and multiple hypotheses testing 
*** NES – normalized enrichment score (ES) Calculated by dividing the actual ES by the mean ES against all permutations 
performed. A positive score indicates up-regulation of the gene-set in KO mice as compared to WT-untreated mice. A 
negative score indicates down-regulation of the gene-set in KO mice as compared to WT-untreated mice.  
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Figure legends 
 
Fig. S1: Schematic representation of the experiment design 
A. The microarray part of the study. In green – animals, data and analyses related to the 
SMIT1 colony; in red – animals, data and analyses related to the IMPA1 colony; in black 
– analyses performed on the combined data obtained from both colonies. 
B. The behavioral part of the study. Black arrows denote the beginning of rotenone 
(purple) and Li (blue) treatment. Colored arrows denote the behavioral experiments; red – 
rotarod and hanging wire tests, blue – FST, orange – amphetamine-induced 
hyperlocomotion.  
 
Fig. S2: Statistical analysis of the raw data of the microarrays 
Three-way mixed model ANOVA carried out to analyze the combined effect of lithium in 
both colonies revealed that the major source of variation between the groups was the 
colony. Type=treatment (Li or regular food), batch=random effect determined by 
principal component analysis (PCA), colony=IMPA1 or SMIT1. 
 
Fig. S3: Hierarchal clustering of all genes differentially expressed in Li-treated mice 
from either of the colonies or in one of the KOs  
Two-way ANOVA was carried out separately in each colony to reveal genes the 
expression of which was affected by Li treatment or KO of either IMPA1 or Slc5a3 as 
compared to WT-untreated mice. 4,643 genes differentially expressed (p<0.05) by either 
Li treatment or gene KO in either of the two colonies were used for the analysis. Signals 
from both colonies were used for the calculation of z-scores. The mice created two major 
clusters corresponding to the two colonies (IMPA1 and SMIT1). Highlighted in turquoise 
is the only gene cluster presenting similar expression pattern in the two colonies. Among 
the two sets of colored bars below the figure the upper represents the colony (blue – 
SMIT1, orange – IMPA1) and the lower - the type of mice (yellow – WT-untreated, pink 
– KO, grey – WT-Li treated).  
 
Fig. S4: Functional annotation of the gene cluster showing similar expression 
pattern between the IMPA1 and SMIT1 colonies 
Functional analysis of the gene cluster with similar expression between the two 
colonies (highlighted in turquoise in Fig. S2A) using DAVID software showed that 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
31
8.
1 
: P
os
te
d 
31
 A
ug
 2
01
1
most of the functional annotations of the genes composing the cluster are related to 
mitochondrial respiration. 
 
Fig. S5: DAVID Functional annotation tool reveals enrichment in mitochondria-
related genes among genes with differential expression in KO mice and Li-treated 
mice in both SMIT1 and IMPA1 colonies  
A list of significantly enriched terms (p<0.05, FDR<0.05) among genes with similar 
differential expression (p<0.0.5) in KO mice and Li-treated WT mice compared to WT-
untreated mice.  
A. Annotation clustering of 654 genes meeting the criteria in the SMIT1 colony.  
B. Annotation clustering of 159 genes meeting the criteria in the IMPA1 colony.  
 
Fig. S6: Ingenuity pathway analysis (IPA) shows great similarity between Li 
treatment, IMPA1 KO and Slc5a3 KO  
We used the IPA software to compare canonical pathways and biological functions 
significantly affected in four groups of mice – IMPA1 KO, SMIT1 KO, Li-treated mice in 
the IMPA1 colony (IMPA_Li) and Li-treated mice in the SMIT1 colony (SMIT_Li).   
A. Biological functions significantly affected by Li treatment and by IMPA1 or SMIT1 
KO. Similarity is often more pronounced between Li treatment and KO in a given colony 
than between Li treatment in the two colonies.  
B. The only three common canonical pathways significantly affected by Li treatment and 
by IMPA1 or SMIT1 KO were all related to mitochondrial function. The Y axes represent 
–log(p-value) of Fisher’s exact test for the significance of the pathway/biological 
function. The red lines represent significance threshold corresponding to a p-value of 
0.05.     
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Fig. S1: Schematic representation of the study design 
Three-way mixed 
model ANOVA 
Two-way ANOVA Two-way ANOVA 
Rotenone
Lithium
Day: 0 15 29 30 31
Hierarchical Clustering  Hierarchical Clustering Hierarchical Clustering 
Mitochondrial 
Function 
Bioinformatics analysis Bioinformatics analysis 
IMPA1 colony 
WT-untreated, WT Li-treated,  
SMIT1 KO 
Microarray hybridization 
RNA extraction from frontal 
cortex  
SMIT1 colony 
WT-untreated, WT Li-treated,  
SMIT1 KO 
Microarray hybridization 
RNA extraction from frontal 
cortex  
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Fig. S2: Statistical analysis of the raw data of the microarrays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S3: Hierarchal clustering of all genes differentially expressed in Li-treated mice from 
either of the colonies or in one of the Kos 
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Fig. S4: Functional annotation of the gene cluster showing similar expression pattern 
between IMPA1 and SMIT1 colonies 
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Fig. S5: DAVID Functional annotation tool reveals enrichment in mitochondria-
related genes among genes with differential expression in KO mice and Li-treated 
mice in both colonies  
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